SCHEMBL6729359

SCHEMBL6729359

NS(=O)(=O)c1ccc(-c2c(-c3ccc(Br)c(Br)c3)noc2C(F)(F)F)cc1F

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.46
PTGS1 P23219 5/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
CA4 P22748 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
KIF11 P52732 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
BRD3 Q15059 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722957 0.91 PTGS2 (0.50) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6719180 0.90 PTGS2 (0.46) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6726400 0.90 PTGS2 (0.46) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6721887 0.90 PTGS2 (0.53) PTGS2PTGS1ESR1ESR2FFAR4
SCHEMBL6726040 0.90 PTGS2 (0.48) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6728996 0.89 PTGS2 (0.46) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6722747 0.88 PTGS2 (0.46) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6732140 0.88 PTGS2 (0.46) PTGS2PTGS1ESR1ESR2F2
SCHEMBL6722713 0.87 PTGS2 (0.60) PTGS2PTGS1ESR1ESR2CA4
SCHEMBL6729199 0.87 PTGS2 (0.42) PTGS2PTGS1ESR1ESR2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885ESR1 1770/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885ESR1 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.